Hypofractionated Radiosurgery to Treat Residual/recurrent Non Secreting Pituitary Adenoma (HYPOADENO)

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Status

Active, not recruiting

Conditions

Pituitary Neoplasms

Pituitary Adenoma

Treatments

Radiation: hypofractionated radiosurgery

Study type

Interventional

Funder types

Other

Identifiers

NCT06826170

HYPO_ADENO

Details and patient eligibility

About

Single session stereotactic radiosurgery (SRS) is commonly used for patients with non-functioning adenomas. However the SRS can be limited by the proximity of the tumor with the surrounding critical structures (i.e., the optic chiasm).

The goal of the present prospective phase II trial is to investigate early and early delayed toxicity for cranial nerves and pituitary function after hypofractionated stereotactic radiotherapy/multisession radiosurgery (hSFRT/mSRS) in residual/ recurrent non secreting pituitary adenomas. Secondary end points are late toxicity and tumour growth local control.

All the enrolled patients will undergo radiosurgical treatment with a hypofractionation schedule Following radiotherapy, follow-up will be scheduled every 6 months during the first year post-radiosurgery and then annually, with the same tests.

The baseline examination and the follow-up assessment will include magnetic resonance imaging (MRI), full blood counts and blood chemistry tests, neuro-ophtalmology evaluation, physical and psychological examination that included a quality-of-life (EORTC Quol 30; BN 20) and a Hospital Anxiety and Depression Scale (HADS).

Full description

Aims The main aim of our study is to analyze the effect of 5-session hypofractionated radiotherapy/multisession radiosurgery in treating NFAs in terms of toxicity and local control.

Study design This study is an exploratory study: patient's and treatment's data will be prospectively collected in a database and they will then be described and analyzed.

Criteria of analysis

All these points will be recorded and analyzed:

Local control measured from the date of mSRS until progression or death, censored at the time of last clinical follow-up or imaging.
Overall survival measured from the date of diagnosis until death, censored at the time of last clinical follow-up or imaging.
Visual acuity improvement/worsening will be defined by reading increases/decreases equal of 1 or more lines; visual field will be considered improved or worsened for decreases or increase in the extension of the defect area. In order to compare pre- and post-treatment data, the results will be registered.
Pituitary toxicity will be defined as a clinically relevant reduction compared to the baseline of ACTH, GH, TSH, testosterone in men, period disturbances in women, new onset of diabetes insipidus due to ADH deficiency. Hormonal changes will be defined relevant if a medical therapy change\introduction become mandatory.
Other treatment-related toxicity based on CTCAE v4.0.
Presence of adverse events based on CTCAE v4.0.
Quality of life evaluated by "Quality of life EORTC - QLQ C30 and BN20" and "Hospital Anxiety and Depression Scale (HADS)". (25-28) (Appendix 1 and 2)

Study population Patients suffering from recurrent/residual non secreting pituitary adenoma. Twenty-five patients will be enrolled.

Study treatment Patients will receive hSFRT/mSRS in 5 consecutive days over 7 elapsed days, with extension over a weekend allowed.

Radiation treatment features Following sub-total surgery or in case of progressive disease patients will be enrolled and a CT and MRI simulation will be performed. A treatment for hypofractionated stereotactic radiotherapy/multifraction radiosurgery (hSHRT/mSRS) will be planned. The planning tumor volume (PTV) will be the residual/recurrent tumor + 0-2 mm as defined on the MRI images. To better define the tumor volume T1 with and without contrast enhancement, with and without fat saturation and T2 axial voloumetric sequences will be acquired and then fused. The prescription isodose line will cover at least 95% of the PTV; undercoverage to 90% will be allowed near organs at risk. Normal organ dose constraints will be 98% of the optic pathways receiving less than 27.5 Gy and brainstem maximum point dose of 30 Gy in 5 fractions, undercovering the PTV to meet these limits.

Patient Assessment and Outcome Reporting The baseline examination will include simulation CT and magnetic resonance imaging (MRI), thereafter full blood counts and blood chemistry tests, neuro-ophtalmology evaluation, physical and psychological examination that included a quality-of-life (EORTC Quol 30; BN 20) and a Hospital Anxiety and Depression Scale (HADS).

Following radiotherapy, follow-up will be scheduled every 6 months during the first year post-radiosurgery and then annually, with the same tests.

Tumor progression will be defined according to the modified WHO criteria as an increase in tumor size by 25 percent. Consensus between the two examining radiologists will be achieved if the target lesions selected differed between the two radiologists. In case of tumor progression, patients will be treated at the investigators' discretion.

Toxicity and adverse events will be graded according to the National Cancer Institute Common Toxicity Criteria, version 4.0, with a score of 1 indicating mild adverse effects, a score of 2 moderate adverse effects, a score of 3 severe adverse effects, and a score of 4 life-threatening adverse effects.

Enrollment

25 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Residual or progressive non secreting pituitary adenoma;
Exclusion of other treatment approach (second surgery, wait and scan; suppressive therapy) by a multidisciplinary team
Age ≥ 18 years; KPS ≥ 70
Written privacy consent;
Ability to give informed consent;

Exclusion criteria